Skip to main content

Lumos Diagnostics Holdings Limited (LDX.AX)

Australian Securities Exchange Healthcare Medical - Diagnostics & ResearchView data quality →
30.7Poor

ValueMarkers Composite Index

Top 0%#44,596 of 44,714

DCF data not available

Piotroski
1/9
Weak
Beneish
-0.68
High Risk
Altman
-1.60
Distress
DCF Value
-
N/A
ROIC
-85.8%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Lumos Diagnostics Holdings Limited (LDX.AX) — VMCI valuation read

The headline on Lumos Diagnostics Holdings Limited (LDX.AX) is a 31/100 VMCI score, set against a Healthcare sector median of 50. That 19-point below-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value drag is in the data.

LDX.AX insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** LDX.AX trades at 27.0x earnings, 50% above the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of -1.8x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on LDX.AX.

LDX.AX fell 1.0% over the trailing 7 days, with a -10.6% read on a 30-day basis.

Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.

CEO: Douglas WardAUlumosdiagnostics.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in LDX.AX’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.